THE AURIMUNE PLATFORM
Tumor-Targeted Trojan Horse
- Aurimune can shield toxic substances like TNF from the body. When the Aurimune nanomedicine reaches the tumor, it is sized to pass through the abnormally large gaps that are found in tumor blood vessels.
- The TNF on the Aurimune nanomedicine acts like an anchor and binds strongly to the tumor’s blood vessels.
- In a short period of time, the concentration of Aurimune inside the tumor increases and only trace amounts can be found in the rest of the body.
THE ELEMENTS OF AURIMUNE
Tumor Necrosis Factor
AURIMUNE PLATFORM PRODUCTS
A first generation Aurimune platform nanomedicine, CYT-6091 carries TNF into tumors to disrupt their blood vessels and enable follow-on chemotherapy to penetrate the tumor and kill the cancer cells inside. In a successful Phase I clinical trial, CYT-6091 safely delivered what would have been a toxic but highly effective dose of the anti-cancer agent TNF to patients; dose levels were three times the previous maximum tolerated dose. Tissue samples, taken 24 hours after CYT-6091 administration, showed that the nanomedicine had concentrated inside tumor tissues, not inside surrounding healthy tissue.
A Phase II clinical trial will treat non small-lung cancer patients in combination with standard of care, second line therapy. Additional details related to the Phase II trial will be announced during the summer of 2014.
A second generation Aurimune platform nanomedicine, CYT-21000 carries Taxol (paclitaxel) in addition to TNF. Aurimune is currently the only nanotechnology that has been able to simultaneously deliver a biologic, TNF and a small molecule therapeutic, Taxol, carried by the same nanoparticle.
CytImmune is currently working with the AstraZeneca’s Oncology Innovative Medicines Unit to examine the viability of delivering an AstraZeneca anti-cancer therapy into solid tumors using the Aurimune nanomedicine platform.
Other CytImmune Investigations
CytImmune has successfully linked other anti-cancer agents to the Aurimune platform. These include:
- Interferon (CYT-61000)
- Gemcitabine (CYT-71000)
PARTNERING WITH CYTIMMUNE
Aurimune is the only clinical stage tumor-targeted product that can carry both biologics and small molecule therapeutics.
CytImmune has experience with numerous therapeutic classes of drug enabling them to bind to the Aurimune platform.
CytImmune has a successful track record working with other institutions to integrate existing anti-cancer agents onto the Aurimune nanomedicine, rescuing molecules whose systemic toxicity has stifled clinical development.
NEWS & UPDATES
CytImmune is a global leader in the field of nanomedicine with the successful completion of a Phase I clinical trial of CYT-6091 — the first in a series of products based on the CytImmune’s Aurimune nanomedicine platform. The company has more than 60 issued and pending patents for its colloidal gold nanotechnology in the United States, European Union, Japan and Canada.
Co-Founder, President & CEO
Co-Founder, Chief Scientific Officer
Executive Vice President, Corporate Development and Chief Legal Officer
Chief Financial Officer
BOARD OF DIRECTORS
Chairman, President & CEO, CytImmune
Thoracic surgeon and consultant to financial institutions
President & COO, APCO Worldwide
President & CEO, QRxPharma
Group General Manager, Itanis International, Inc.
Former Acting Deputy Director, National Institute of Standards and Technology
President & CEO, NHM, advisory firm to venture capital companies
Director, Montefiore Einstein Center for Cancer Care
Director General, Cancer Institute Gustave Roussy
15010 Broschart Road
Rockville, MD 20850
Phone: (301) 825-3041